Have you been previously treated for advanced-stage nonsquamous non–small cell lung cancer?

If not, you may be eligible for this study.

A Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel, and Bevacizumab for Advanced Non-squamous Non–Small Cell Lung Cancer (NSCLC)
What does it mean to be diagnosed with advanced-stage nonsquamous non–small cell lung cancer?

Lung cancer forms tumors in the lungs. The most common form of lung cancer is non–small cell lung cancer, or NSCLC. The most common forms of NSCLC include squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.

How will the “stage” of NSCLC be determined?

Your doctor will confirm that you have NSCLC. You will need to have several tests to tell what stage of NSCLC you have. The tests may include a CT scan, an MRI or PET scan, a bone scan, biopsies, and tests to see how well your lungs are working. These tests may help you and your doctor choose the treatment option that is right for you.
What does it mean to have advanced-stage IIIB-T4Nx, IV M1a, or IV M1b NSCLC?

These advanced stages of NSCLC mean that the original cancer formed in the lung may have expanded and spread, or metastasized, beyond the lungs to other parts of the body, such as the lymph nodes.

What are my treatment options?

Patients with advanced-stage NSCLC are treated with a combination of chemotherapies. Some cancer patients elect to enroll in clinical studies that look at new therapies to see if they may help patients.

What is a clinical study?

A clinical study or clinical trial is a way to try new and investigational therapies to see if they will benefit patients. Clinical trials are closely monitored to make sure they follow strict rules to protect patients. Clinical trials may or may not benefit patients.

Why is the E5508 study being done?

This study is being done to find out if the addition of maintenance therapy to standard chemotherapy increases the survival of patients with advanced NSCLC. Although the survival rate in patients with NSCLC is improved with initial combination chemotherapy, we are still trying to find the best maintenance therapy for patients.

What type of treatment will I have?

Treatment options for advanced nonsquamous NSCLC are usually a combination of chemotherapies. This is usually given in 4 cycles. Because the type of treatment you are receiving after your first rounds of combination chemotherapy is being compared, you will not know which treatment you are to receive. This is called randomization. You will be selected randomly by a computer to see which compared therapy you will receive.
How many people will take part in the E5508 study?

Approximately 1495 people in the United States will take part in this study.

Who can participate in the E5508 study?

You may be able to participate if you meet these criteria:

- Be 18 years old or older with confirmed advanced nonsquamous NSCLC
- Have properly working organs
- Have controlled high blood pressure (no higher than 150/100)
- No pregnancy or breast-feeding
- No prior treatment (eg, paclitaxel, pemetrexed, or bevacizumab) for NSCLC
- No prior systemic chemotherapy for advanced-stage lung cancer
- Prior adjuvant (additional) chemotherapy is allowed if at least 12 months have passed since prior chemotherapy administration and registration
- No prior cancers within the past 3 years (except mild cases of some skin cancers)
- No actively progressive brain metastases, serious illnesses, active infection, symptomatic congestive heart failure, unstable chest pains, serious irregular heart rate, or mental illness
- No major surgery or serious injuries within 6 weeks of deciding to participate in this study

*These are the main requirements only. Your doctor will perform a more detailed review of your eligibility if you are interested in participating.
What can I expect to experience during the study?

Your doctor will discuss potential side effects during the study. Please call your health care team as directed by your doctor if the symptoms are severe. Changes to your treatment can be made according to your doctor’s recommendations.

How will I know if the treatment is helping?

Your doctor visits will be a good time to talk about this issue. Tests like you experienced at diagnosis will most likely be done again to compare how you are doing with the study medications. Clear and honest communication with your health care team is the best way to ask questions and express concerns.

What rights will I have if I take part in this study?

Remember, you can withdraw from the study at any time. Participation in a clinical study is completely voluntary. Your health care team will keep you informed with updates about this particular trial as the study progresses. You will sign an informed consent document that provides details about the study and whom to contact regarding your care.

How can I enroll?

If you would like to participate in this trial, let your doctor know. The doctor can tell you if you are eligible, and will supply the resources for enrolling.
Who is conducting the trial?

The Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN) are conducting this trial. ECOG and ACRIN are among the largest cancer research organizations in the United States. They have a network of researchers, physicians, and health care professionals at public and private institutions across the country. ECOG conducts clinical trials in all types of adult cancers. ACRIN conducts studies of innovative imaging modalities and how they can improve the detection and treatment of cancers. ECOG and ACRIN receive funding from the National Cancer Institute (NCI) and other sources. ECOG and ACRIN share the goal of identifying, controlling, effectively treating, and ultimately curing cancer. ECOG and ACRIN provide research results to individuals and the medical community through scientific publications and professional meetings.
How can I learn more about the study?
For more information about the E5508 study, please go to the following Web sites:

• http://www.cancer.gov/clinicaltrials/ECOG-E5508

• ClinicalTrials.gov registration number: NCT01107626:
  http://clinicaltrials.gov/ct/show/NCT01107626

For more information about ECOG-ACRIN visit www.ecog-acrin.org

Reference